文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.

作者信息

He XueChun, Li FaPeng, Zhang Jian, Wen ZhiYing, Li YanXiao, Gao WeiTong, Chen HongXia, Yu YangGuang, Zheng YingYing, Xie Xiang

机构信息

Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China.

Department of Cardiology, The Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, People's Republic of China.

出版信息

Int J Gen Med. 2025 Aug 25;18:4735-4751. doi: 10.2147/IJGM.S531156. eCollection 2025.


DOI:10.2147/IJGM.S531156
PMID:40894438
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12396532/
Abstract

OBJECTIVE: The present study aimed to explore the predictive value and prognosis of apolipoprotein A-I (ApoA-I) in chronic heart failure (CHF) patients. METHODS: We recruited 4442 patients with CHF who were admitted to The First Affiliated Hospital of Xinjiang University Medical University with a period of ten years from July 2012, and the mean follow-up time was 22.75 months. The endpoints were defined as all-cause mortality (ACM), the patients divided into low and high ApoA-I groups according to the optimal cutoff value of the ROC curve from finally analyzed HF patients. RESULTS: In the whole follow-up periods, multivariate Cox regression analysis showed that total CHF patients in low ApoA-I groups had significantly increased risk of ACM as compared with patients in the high ApoA-I group (hazard ratio [HR]=0.702, 95%confidence interval [CI]: 0.603-0.817, P <0.001). This trend was consistent in patients with heart failure with mid-range (HFmrEF) (HR = 0.443, 95% CI: 0.298-0.658, P <0.001) and heart failure with preserved ejection fraction (HFpEF) (HR = 0.704, 95% CI: 0.539-0.919, P = 0.010), but not in heart failure with reduced ejection fraction (HFrEF) (HR = 0.806, 95% CI: 0.582-1.116, P = 0.194). CONCLUSION: The Apolipoprotein A-I concentrations significantly associated with ACM of CHF especially in HFmrEF and HFpEF.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/a6f43b07e6fd/IJGM-18-4735-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/d204d5eae28f/IJGM-18-4735-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/1ab69d37d749/IJGM-18-4735-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/3fd4db8fad02/IJGM-18-4735-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/23f2cf7173d5/IJGM-18-4735-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/bf7bb881eeef/IJGM-18-4735-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/1ba9c97ad18c/IJGM-18-4735-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/2d2788a0b25c/IJGM-18-4735-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/c35bcafc42c6/IJGM-18-4735-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/b4d2fc50ddf5/IJGM-18-4735-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/a6f43b07e6fd/IJGM-18-4735-g0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/d204d5eae28f/IJGM-18-4735-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/1ab69d37d749/IJGM-18-4735-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/3fd4db8fad02/IJGM-18-4735-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/23f2cf7173d5/IJGM-18-4735-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/bf7bb881eeef/IJGM-18-4735-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/1ba9c97ad18c/IJGM-18-4735-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/2d2788a0b25c/IJGM-18-4735-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/c35bcafc42c6/IJGM-18-4735-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/b4d2fc50ddf5/IJGM-18-4735-g0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1163/12396532/a6f43b07e6fd/IJGM-18-4735-g0010.jpg

相似文献

[1]
The Level of Apolipoprotein A-I Is Associated with a Prognosis in Patients with Chronic Heart Failure Especially in HFmrEF and HFpEF: A Retrospective Cohort Study.

Int J Gen Med. 2025-8-25

[2]
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.

Eur J Med Res. 2022-12-29

[3]
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

Cochrane Database Syst Rev. 2022-9-26

[4]
Assessment of the Physical and Emotional Health-Related Quality of Life Among Congestive Heart Failure Patients with Preserved and Reduced Ejection Fraction at a Quaternary Care Teaching Hospital in Coastal Karnataka in India.

Healthcare (Basel). 2025-7-31

[5]
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy.

medRxiv. 2023-5-16

[6]
Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF.

JACC Heart Fail. 2025-3

[7]
Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.

Sci Rep. 2025-8-18

[8]
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis.

J Am Heart Assoc. 2025-6-17

[9]
Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis.

Heart Fail Rev. 2021-9

[10]
Anemia in Heart Failure: Diagnostic Insights and Management Patterns Across Ejection Fraction Phenotypes.

Diagnostics (Basel). 2025-8-19

本文引用的文献

[1]
Characterization of ischemic etiology in heart failure with reduced ejection fraction randomized clinical trials: A systematic review and meta-analysis.

Eur J Intern Med. 2025-4

[2]
Exercise Therapy Rescues Skeletal Muscle Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF.

JACC Basic Transl Sci. 2024-9-18

[3]
Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction.

Clin Res Cardiol. 2025-1-15

[4]
HDL Levels as a Novel Predictor of Long-Term Adverse Outcomes in Patients with Heart Failure: A Retrospective Cohort Study.

J Inflamm Res. 2024-9-10

[5]
Pathophysiological insights into HFpEF from studies of human cardiac tissue.

Nat Rev Cardiol. 2025-2

[6]
Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.

J Cardiovasc Transl Res. 2024-12

[7]
Global epidemiology of heart failure.

Nat Rev Cardiol. 2024-10

[8]
Remnant cholesterol is associated with unstable carotid plaque in a neurologically healthy population.

Stroke Vasc Neurol. 2025-2-25

[9]
The neutrophil-to-apolipoprotein A1 ratio is associated with adverse outcomes in patients with acute decompensated heart failure at different glucose metabolic states: a retrospective cohort study.

Lipids Health Dis. 2024-4-22

[10]
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.

N Engl J Med. 2024-5-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索